Neste Flashdirect, iremos debater sobre os estudos SKYLIGHT 1 e 2. Ambos embasaram a aprovação pelo FDA do Fezolinetant para tratamento de sintomas vasomotores moderados e graves nas pacientes com menopausa.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
